<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004769</url>
  </required_header>
  <id_info>
    <org_study_id>199/11770</org_study_id>
    <secondary_id>URMC-583</secondary_id>
    <secondary_id>URMC-445</secondary_id>
    <nct_id>NCT00004769</nct_id>
  </id_info>
  <brief_title>Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy</brief_title>
  <official_title>Myotonic Dystrophy:Muscle Wasting and Altered Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Examine the interrelationships between muscle wasting (phenotype), the degree&#xD;
      of myotonic dystrophy (DM) gene expression (genotype) in patients with DM.&#xD;
&#xD;
      II. Characterize the insulin resistance in these patients. III. Assess the glucose uptake in&#xD;
      the leg and forearm tissues of these patients.&#xD;
&#xD;
      IV. Determine the stability of the DM gene lesion in muscles over a 5-10 year period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients are placed on a meatless diet 3 days prior to study entry.&#xD;
&#xD;
      During the first 5-day hospital stay, patients receive an oral glucose tolerance test, an&#xD;
      intravenous glucose tolerance test, and an intravenous infusion of insulin and glucose&#xD;
      (dextrose) to determine the degree of insulin resistance. Patients also receive dual x-ray&#xD;
      absorptiometry (DEXA) scan and total body potassium count to measure muscle mass. Patients&#xD;
      undergo strength testing and physical fitness screening. A needle biopsy is performed to&#xD;
      investigate the genetic alterations associated with this disease.&#xD;
&#xD;
      During the second 3-day hospital stay, patients receive an intravenous infusion of insulin,&#xD;
      stable isotopic glucose, and stable isotopic glycerol.&#xD;
&#xD;
      During the third 3-day hospital stay, a catheter is placed in the femoral artery, femoral&#xD;
      vein, and in each arm. Patients receive an infusion of stable isotopic glucose, stable&#xD;
      isotopic phenylalanine, and insulin. Measurements of the balance of amino acids and glucose&#xD;
      across the forearm and leg are completed. Green dye is infused to measure blood flow in the&#xD;
      leg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1993</start_date>
  <completion_date type="Actual">March 2000</completion_date>
  <primary_completion_date type="Actual">March 2000</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative myometry (QMT)</measure>
    <time_frame>Visit 1</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Myotonic Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Myotonic dystrophy</arm_group_label>
    <description>Subjects with myotonic dystrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease controls 1</arm_group_label>
    <description>Subjects with FSHD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease controls 2</arm_group_label>
    <description>Subjects with CMT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        National sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically mild or moderate myotonic dystrophy (DM), proximal myotonic myopathy&#xD;
             (PROMM), facioscapulohumeral muscular dystrophy (FSH) or, Charcot-Marie-Tooth (CMT)&#xD;
&#xD;
          -  Mild or moderate DM defined as: Mild muscle weakness in the limbs, modest facial&#xD;
             weakness, and mild grip myotonia; Moderate muscle weakness in the limbs, typical DM&#xD;
             facies, and prominent grip myotonia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or concurrent therapy&#xD;
&#xD;
          -  Obese&#xD;
&#xD;
          -  Concurrent acute illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard T. Moxley, III</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Richard T Moxley</investigator_full_name>
    <investigator_title>Professor Of Neurology</investigator_title>
  </responsible_party>
  <keyword>Genetic diseases</keyword>
  <keyword>Myotonic muscular dystrophy</keyword>
  <keyword>Facioscapulohumeral muscular dystrophy</keyword>
  <keyword>CMT</keyword>
  <keyword>Rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

